Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Brain protein burden is related to intravoxel incoherent motion: PET-MR imaging study.

Frontiers in neuroscience·2026
Same author

SMILES-based degree molecular descriptors and machine learning for QSPR modeling of anti-alkaptonuria drugs.

Frontiers in chemistry·2026
Same author

Predicting Autopsy-Confirmed Neuropathology across Clinical, Neuroimaging, and CSF Biomarkers using Machine Learning.

bioRxiv : the preprint server for biology·2026
Same author

A Variational Mean-Field Control Framework for Graph Representation Learning.

IEEE transactions on pattern analysis and machine intelligence·2026
Same author

An <i>APOE</i> *4-Informed Genomic Atlas of the X Chromosome in Alzheimer's Disease.

medRxiv : the preprint server for health sciences·2026
Same author

Effects of α-synuclein pathology on synaptic dysfunction and clinical outcomes in normal aging.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
関連記事をすべて見る

関連する実験動画

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

創薬

Tiansheng Wang1, Yongjie Lai2, Elizabeth C Mormino3

  • 1Universtiy of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
まとめ
この要約は機械生成です。

スタチンは認知症予防に全体的なベネフィットを示さなかった。しかし、アルツハイマー病のリスクが高い（非APOE-PRS）個人で健康的な食事をしている人は、スタチンからベネフィットを得る可能性があり、個別化された認知症予防戦略を示唆している。

キーワード:
創薬スタチン認知症アルツハイマー病個別化医療

さらに関連する動画

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

関連する実験動画

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

科学分野:

  • 神経学
  • 薬理学
  • 機械学習

背景:

  • スタチンの認知症リスクに対する効果は、集団の異質性により、一貫性のない結果が得られる可能性があり、依然として議論の的となっています。
  • スタチンからベネフィットを得る患者サブグループを特定することは、個別化医療にとって重要です。

研究 の 目的:

  • 因果推論機械学習を用いて、模倣された臨床試験におけるスタチンの発症性認知症に対する異質的治療効果（HTEs）を評価すること。
  • スタチンの有効性に差がある特定の患者特性を特定すること。

主な方法:

  • 2009年から2017年までのUK Biobankデータを用いて、スタチン使用者と非使用者（55歳以上）を比較する模倣標的臨床試験を実施しました。
  • 傾向スコアマッチングデータに反復因果森林（iCF）アルゴリズムを適用して、HTEsを特定しました。
  • 遺伝的要因（APOE遺伝子型、nonAPOE-PRS、スタチン-PRS）およびライフスタイルを、効果修飾因子として分析しました。

主要な成果:

  • 全体として、スタチンは、発症性認知症のリスクを有意に低減しませんでした（aRD -0.01%）。
  • iCFは有意なHTE（P=0.001）を特定しました。
  • 高非APOE-PRSおよび健康的な食事習慣を持つ患者が最大のベネフィットを示しました（aRD -1.18%）。高非APOE-PRS単独では、より小さなベネフィットを示しました（aRD -0.47%）。

結論:

  • スタチンは、研究対象集団において、認知症に対する一般的な保護効果を提供しません。
  • アルツハイマー病のリスクが高い（nonAPOE-PRS）特定のサブポピュレーションで、健康的な食事習慣を持つ人々は、スタチン使用からベネフィットを得る可能性があります。